title: How harmless is FFA enhancement?
abstract: Standard heparin as well as low molecular weight heparin (LMWH) increase lipid levels in serum. It has been reported that a diet rich in long chain saturated fatty acids can enhance the susceptibility to experimental thrombosis. The mechanism by which serum fatty acids may provoke thrombosis is not clear. It is possible that the fatty acids change the properties of the cell membrane and thereby modify the response of platelets to aggregating agents. Heparin and its LMW fractions, by mobilising lipoprotein lipase that hydrolyses serum triglycerides (TG), cause the serum TG to increase, a well known "clearing effect' of heparin in turbid lipemic plasma. This effect may have no significance when it lasts for a short time; however, a long-lasting heparin effect on TG serum levels may have important consequences. The purpose of this study was to examine the time span of the action of heparin and its fractions and to investigate variations in the concentration of digoxin, which is a compound with narrow therapeutic width. The investigated substances after 2 days administration, provoked serum concentration increases of free fatty acids (FFA), TG and HDL-C. Seven days after stopping drug administration, FFA and HDL-C levels remained high, while triglycerides declined. Serum total cholesterol remained unchanged throughout. Digoxin levels increased non-significantly after heparin administration and during swimming stress, while a lipid diet caused a serum digoxin concentration increase.
authors.affiliation: Department of Pharmacology, Athens University Medical School, Greece.
authors.forename: C
authors.initials: C
authors.lastname: Tesserommatis
authors.forename: C
authors.initials: C
authors.lastname: Tsopanakis
authors.forename: G
authors.initials: G
authors.lastname: Symeonoglou
authors.forename: M
authors.initials: M
authors.lastname: Loukissa
authors.forename: E
authors.initials: E
authors.lastname: Kouvarou
authors.forename: D D
authors.initials: DD
authors.lastname: Varonos
mesh_terms: D000818:Animals; D001835:Body Weight; D002784:Cholesterol / Q000097:blood; D004077:Digoxin / Q000097:blood* / Q000494:pharmacology; D004347:Drug Interactions; D005230:Fatty Acids, Nonesterified / Q000097:blood*; D006493:Heparin / Q000494:pharmacology*; D017762:Nadroparin / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D005230:Fatty Acids, Nonesterified; D017762:Nadroparin; D014280:Triglycerides; D004077:Digoxin; D006493:Heparin; D002784:Cholesterol